Patents by Inventor Kai Lovis

Kai Lovis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220234996
    Abstract: The present invention relates to a novel and improved process for preparing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid of the formula (I), to the compound of the formula (I) in crystalline form and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular, cardiopulmonary and cardiorenal disorders.
    Type: Application
    Filed: April 18, 2022
    Publication date: July 28, 2022
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Peter Fey, Philipp Rubenbauer, Kai Lovis, Britta Olenik, Julia Küsel, Felix Spindler
  • Patent number: 11344519
    Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: May 31, 2022
    Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER AKTIENGESELLSCHAFT
    Inventors: Anke Stroyer, Carmen Lobback, Peter Serno, Philipp Rubenbauer, Kai Lovis, Heiko Schirmer, Danja Grossbach, Donald Bierer, Britta Olenik, Tia Jacobs, Julia Küsel
  • Publication number: 20220153699
    Abstract: The present invention relates to a novel and improved method for preparing 4-amino-5-methylpyridone of the formula (I) which is an intermediate in the preparation of the MR antagonist finerenone.
    Type: Application
    Filed: February 28, 2020
    Publication date: May 19, 2022
    Inventors: Johannes Platzek, Kai Lovis
  • Patent number: 11332435
    Abstract: The present invention relates to a novel and improved process for preparing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid of the formula (I), to the compound of the formula (I) in crystalline form and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular, cardiopulmonary and cardiorenal disorders.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: May 17, 2022
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Peter Fey, Philipp Rubenbauer, Kai Lovis, Britta Olenik, Julia Kusel, Felix Spindler
  • Publication number: 20220098201
    Abstract: Compound (III) which is the crystalline form of [4-{[4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2, -f] [1,2,4]triazin-7-yl]methyl}piperazin-2-one hydrochloride] which is the monohydrate, processes for its preparation, pharmaceutical compositions comprising it and its use in the control of disorders, including cancer.
    Type: Application
    Filed: January 27, 2020
    Publication date: March 31, 2022
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Jörg GRIES, Johannes PLATZEK, Claus-Christian HÄSELHOFF, Kai LOVIS
  • Publication number: 20210179541
    Abstract: The present invention relates to a novel and improved process for preparing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid of the formula (I), to the compound of the formula (I) in crystalline form and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular, cardiopulmonary and cardiorenal disorders.
    Type: Application
    Filed: November 26, 2018
    Publication date: June 17, 2021
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Peter FEY, Philipp RUBENBAUER, Kai LOVIS, Britta OLENIK, Julia KUSEL, Felix SPINDLER
  • Publication number: 20210163474
    Abstract: The present invention relates to a novel and improved process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I) and also to the preparation of the enantiomer (Ia) by racemate resolution using chiral substituted tartaric acid esters of the general formulae (IIIa) and (IIIb) where Ar represents a substituted or unsubstituted aromatic or heteroaromatic radical.
    Type: Application
    Filed: April 23, 2019
    Publication date: June 3, 2021
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Johannes PLATZEK, Kai LOVIS, Winfried JOENTGEN
  • Publication number: 20210113504
    Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
    Type: Application
    Filed: December 23, 2020
    Publication date: April 22, 2021
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Anke Stroyer, Carmen Lobback, Peter Serno, Philipp Rubenbauer, Kai Lovis, Heiko Schirmer, Danja Grossbach, Donald Bierer, Britta Olenik, Tia Jacobs, Julia Küsel
  • Patent number: 10905667
    Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: February 2, 2021
    Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER AKTIENGESELLSCHAFT
    Inventors: Anke Stroyer, Carmen Lobback, Peter Serno, Philipp Rubenbauer, Kai Lovis, Heiko Schirmer, Danja Grossbach, Donald Bierer, Britta Olenik, Tia Jacobs, Julia Küsel
  • Publication number: 20200030270
    Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
    Type: Application
    Filed: July 24, 2018
    Publication date: January 30, 2020
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Anke Stroyer, Carmen Lobback, Peter Serno, Philipp Rubenbauer, Kai Lovis, Heiko Schirmer, Danja Grossbach, Donald Bierer, Britta Olenik, Tia Jacobs, Julia Kusel
  • Patent number: 10494372
    Abstract: The present invention relates to a novel method of preparing copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride. The present invention also relates to copanlisib dihydrochloride hydrates as compounds.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: December 3, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Jan-Georg Peters, Philipp Rubenbauer, Daniel Götz, Danja Großbach, Franz-Josef Mais, Heiko Schirmer, Juergen Stiehl, Kai Lovis, Andreas Lender, Martin Seyfried, Theodor Zweifel, Maurus Marty, Günter Weingärtner
  • Publication number: 20180282337
    Abstract: The present invention relates to a novel method of preparing copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride. The present invention also relates to copanlisib dihydrochloride hydrates as compounds.
    Type: Application
    Filed: November 5, 2015
    Publication date: October 4, 2018
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Jan-Georg PETERS, Philipp RUBENBAUER, Daniel GÖTZ, Danja GROßBACH, Franz-Josef MAIS, Heiko SCHIRMER, Juergen STIEHL, Kai LOVIS, Andreas LENDER, Martin SEYFRIED, Theodor ZWEIFEL, Maurus MARTY, Günter WEINGÄRTNER
  • Patent number: 10035803
    Abstract: The present invention relates to a novel method of preparing copanlisib, and copanlisib dihydrochloride, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said copanlisib.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: July 31, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Jan-Georg Peters, Jürgen Stiehl, Kai Lovis
  • Publication number: 20170327505
    Abstract: The present invention relates to a novel method of preparing copanlisib, and copanlisib dihydrochloride, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said copanlisib.
    Type: Application
    Filed: November 5, 2015
    Publication date: November 16, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Jan-Georg PETERS, Jürgen STIEHL, Kai LOVIS
  • Patent number: 9359306
    Abstract: The invention relates to a novel process for the preparation of pan-CDK inhibitors of the formula (I), and intermediates of the preparation.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: June 7, 2016
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Joachim Krüger, Jörg Gries, Kai Lovis, Jorma Haβfeld
  • Publication number: 20130245261
    Abstract: The invention relates to a novel process for the preparation of pan-CDK inhibitors of the formula (I), and intermediates of the preparation.
    Type: Application
    Filed: September 20, 2011
    Publication date: September 19, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Joachim Krüger, Jörg Gries, Kai Lovis, Jorma Hassfeld
  • Publication number: 20080269512
    Abstract: A method for the deoxofluorination of a ketone for the production of a geminal difluoride compound in an industrial scale comprising the following steps: preparing an educt mixture comprising a ketone and a dialkylaminosulfur trifluoride, letting flow the educt mixture into a reaction chamber of defined length, diameter and volume, with a flow path having a width perpendicular to the direction of the flow in the range of 1-10 mm, at a temperature of at least 75° C. up to 120° C., preferably between 80 and 100° C., to perform the deoxofluorination reaction and obtaining a product mixture to quench the product mixture with a basic aqueous solution in a cooled reservoir vessel.
    Type: Application
    Filed: August 20, 2007
    Publication date: October 30, 2008
    Inventors: Kai Lovis, Jens Geisler, Ralf Senzel, Michael Formell, Christian Finke, Michael Nau, Kathrin Schulz, Uwe Budde, Uwe Thiel
  • Patent number: 7067683
    Abstract: This invention describes a safe method for the production of sulfamoyl chloride from chlorosulfonyl isocyanate and formic acid in the presence of a amide catalyst, taming the hazardous nature of this reaction by circumventing heat accumulation processes, as well as the sulfamoylation of alcohols and phenols with the resulting sulfamoyl chloride in N,N-dimethyl acetamide or N-methyl pyrrolidone thereby avoiding the formation of side-products which were inevitable with the methods of the prior art using dimethyl formamide or dichloromethane as a solvent. The current invention allows industrial scale applications and describes as an example the process of manufacture of the biologically active compound 17?-Hydroxyestra-1,3,5(10)-triene-3-yl sulfamate.
    Type: Grant
    Filed: December 23, 2002
    Date of Patent: June 27, 2006
    Assignee: Schering AG
    Inventors: Jens Geisler, Frank Schneider, Fernando Lopez Holguin, Kai Lovis
  • Patent number: 6652782
    Abstract: The invention relates to a multi-stage method for producing gas-filled microcapsules. In one stage of the method, the substance that forms the coat is polymerized. The microcapsules are formed in a physically and/or temporally separate stage, by means of a structuring process. The polymerization is carried out with moderate stirring, while the microcapsules are structured in dispersing conditions.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: November 25, 2003
    Assignee: Schering Aktiengesellschaft
    Inventors: Uwe Budde, Andreas Briel, Georg Rossling, Kai Lovis, Wolfgang Schmidt, Hans-Ulrich Moritz, Michael Gottfried, Jan-Peter Ingwersen
  • Publication number: 20030171346
    Abstract: This invention describes a safe method for the production of sulfamoyl chloride from chlorosulfonyl isocyanate and formic acid in the presence of a amide catalyst, taming the hazardous nature of this reaction by circumventing heat accumulation processes, as well as the sulfamoylation of alcohols and phenols with the resulting sulfamoyl chloride in N,N-dimethyl acetamide or N-methyl pyrrolidone thereby avoiding the formation of side-products which were inevitable with the methods of the prior art using dimethyl formamide or dichloromethane as a solvent. The current invention allows industrial scale applications and describes as an example the process of manufacture of the biologically active compound 17&bgr;-Hydroxyestra-1,3,5(10)-triene-3-yl sulfamate.
    Type: Application
    Filed: December 23, 2002
    Publication date: September 11, 2003
    Applicant: Schering AG
    Inventors: Jens Geisler, Frank Schneider, Fernando Lopez Holguin, Kai Lovis